Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.
The novel alkylating dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) was evaluated for acute toxicity and antitumor activity in mice, with melphalan as a reference. To determine a safe and tolerable dose for efficacy studies the acute toxicity following intravenous injection in the tail vein was monitored using a 14-day schedule with up to four doses. The highest tested dose, 25 micromoles/kg, was considered close to this level, with minor effects on body weight gain but significant effects on hematological parameters. Melphalan and J1 appeared equitoxic with no statistically significant differences. Subsequently a mouse hollow fiber model was employed with subcutaneous implantation of fibers containing human tumor cells. Three different human tumor cell lines as well as two samples of primary human tumor cells (ovarian carcinoma and chronic lymphatic leukemia) were used as tumor models. At the dose level tested there was a marked and statistically significant decrease in both T-cell leukemia CCRF-CEM and small cell lung cancer NCI-H69 tumor cell growth and viability in response to J1 as compared with both placebo and melphalan treated groups. In primary ovarian carcinoma cells only J1 treatment resulted in significant tumor regression (net cell kill). In summary the results indicate that, despite an expected short half time in the blood circulation, the promising in vitro data from the previous studies of J1 seems translatable into the in vivo situation. At equal doses of alkylating units J1, compared to melphalan, was more active in the mouse hollow-fiber model, but showed similar general toxicity.
Department of Medical Sciences, Division of Clinical Pharmacology, Uppsala University, Sweden.
Joachim
J
Gullbo
Elin
E
Lindhagen
Saadia
S
Bashir-Hassan
Marcus
M
Tullberg
Hans
H
Ehrsson
Rolf
R
Lewensohn
Peter
P
Nygren
Manuel
M
De La Torre
Kristina
K
Luthman
Rolf
R
Larsson
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology* / Q000633:toxicity*; D045744:Cell Line, Tumor; D004151:Dipeptides / Q000494:pharmacology* / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D008297:Male; D008558:Melphalan / Q000494:pharmacology; D051379:Mice; D023382:Toxicity Tests, Acute
D018906:Antineoplastic Agents, Alkylating; D004151:Dipeptides; C482580:L-melphalanyl-p-L-fluorophenylalanine ethyl ester; D008558:Melphalan